The turbulent late 1960s were marked by Vietnam protests, Woodstock, and man’s first steps on the Moon. It was also the dawn of the era of colonoscopy, one of the most significant tools we have against colorectal cancer—the third most commonly diagnosed cancer and second leading cause of cancer death in the US.
“Day Zero Diagnostics: Modernizing Infectious Disease Diagnosis” Boston-based start-up Day Zero Diagnostics is developing a sequencing-based rapid diagnostic that identifies both the species and the antibiotic resistance profile of a bacterial pathogen in only hours, not days, which for patients could mean the difference between life or death. In this interview, CEO and Co-founder Jong Lee, MBA talks about his early inspiration and his experiences in co-founding the company, his current priorities, and what’s next for Day Zero.
London-based oncology diagnostics start-up BeamLine Diagnostics is developing a point-of-care (POC) biopsy triaging and stratification system, called Solas. Solas is estimated to reduce the total number of samples within pathology by approximately 50%, alleviating current system stress. In this candid interview, co-Founder & CEO Dr. Liberty Foreman talks about her inspiration and early experiences in founding the company, her current priorities, and what’s next for BeamLine.